2020
A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users
Lazorwitz A, Seale R, Davis A, Guiahi M. A pilot study on the effect of isotretinoin on serum etonogestrel concentrations in contraceptive implant users. Contraception 2020, 102: 58-60. PMID: 32325076, PMCID: PMC7272275, DOI: 10.1016/j.contraception.2020.04.011.Peer-Reviewed Original ResearchConceptsSerum etonogestrel concentrationsContraceptive implant usersEtonogestrel concentrationsReproductive-age womenOvulatory suppressionContraceptive implantsImplant usersHealthy reproductive-age womenEffect of isotretinoinEtonogestrel contraceptive implantIsotretinoin therapyPharmacokinetic interactionsReliable contraceptionIsotretinoinSmall studyPilot studyPotent teratogenBaselineWomenSignificant changesAppropriate optionImplantsEtonogestrelPatientsPregnancy
2019
Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital
Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital. Journal Of Anesthesia 2019, 34: 294-297. PMID: 31865457, PMCID: PMC8496978, DOI: 10.1007/s00540-019-02725-2.Peer-Reviewed Original ResearchConceptsHormonal contraceptionDrug-drug interactionsUnintended pregnancyPost-operative counselingRetrospective chart reviewChart reviewRisk patientsHormonal contraceptivesColorado HospitalAcademic hospitalFDA labelContraceptive methodsSugammadexContraceptionPatientsWomenUnnecessary riskPregnancyHospitalCounselingExposureMedicationsContraceptivesProgestinsEstrogen
2015
Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women?
Lazorwitz A, Sheeder J, Teal S, Guiahi M. Does the expectation or perception of noncontraceptive benefits lead to higher rates of short-acting reversible contraceptive continuation for adolescents and young adult women? Contraception 2015, 91: 380-385. PMID: 25684618, DOI: 10.1016/j.contraception.2015.02.003.Peer-Reviewed Original ResearchConceptsNoncontraceptive benefitsMonths of useContraceptive continuationYoung womenNew contraceptive developmentYoung women ages 13Post-visit surveysWomen ages 13Young adult womenContinuation ratesStudy participantsAdult womenGreater continuationWomenMonthsContraceptive developmentAge 13High rateContraceptionAdolescentsConcordanceBenefits leadPatientsClinicInitiation